Substance / Medication

Saquinavir

SNOMED 372530001 UMLS C0286738

Overview

Active Ingredient

saquinavir

RxNorm CUI

83395

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

AIDS

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

9 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment

NCT00379405Phase 4Completed30 enrolled

Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

NCT00050180Phase 4Completed81 enrolled

A PK and Salvage Study for Children With HIV-infection

NCT00476359Phase 4Completed50 enrolled

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

NCT00192660Phase 4Completed80 enrolled

Lopinavir Capsules to Kaletra or Invirase Tablets

NCT00438152Phase 4Completed53 enrolled

View all 9 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.

Ridjab Denio A, Ivan Ignatius, Budiman Fanny et al. · Medicine (Baltimore) · 2021

PMID: 34397829Meta-AnalysisFull text (PMC)

Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients.

Boffito Marta, Jackson Akil, Pozniak Anton et al. · Drugs R D · 2015

PMID: 25742730RCTFull text (PMC)

Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.

Ieiri Ichiro, Tsunemitsu Shyohei, Maeda Kazuya et al. · J Clin Pharmacol · 2013

PMID: 23381882RCT

Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects.

Yerino Gustavo A, Halabe Emilia K, Zini Elvira et al. · Arzneimittelforschung · 2011

PMID: 21950153RCT

Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.

Schmitt C, Kaeser B, Riek M et al. · Int J Clin Pharmacol Ther · 2010

PMID: 20197013RCT

Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.

Kaeser Benoite, Zandt Hagen, Bour Fabrice et al. · Antimicrob Agents Chemother · 2009

PMID: 19015329RCTFull text (PMC)

The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

Winston Alan, Mallon Patrick W G, Satchell Claudette et al. · Clin Infect Dis · 2007

PMID: 17479946RCT

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

Chetchotisakd P, Anunnatsiri S, Mootsikapun P et al. · HIV Med · 2007

PMID: 17944686RCT

Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.

Autar Reshma Saskia, Wit Ferdinand W N M, Sankote Jongkol et al. · AIDS · 2007

PMID: 17630547RCT

Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.

Sekar Vanitha J, Lefebvre Eric, Mariën Kris et al. · Ther Drug Monit · 2007

PMID: 18043478RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Saquinavir (substance)
SNOMED CT: 372530001
UMLS CUI: C0286738
RxNorm CUI: 83395

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.